Teva Pharms Intl Drug Patent Portfolio

Teva Pharms Intl owns 2 orange book drugs protected by 11 US patents Given below is the list of Teva Pharms Intl's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6987103 Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents 26 Oct, 2026
Active
US7387793 Modified release dosage forms of skeletal muscle relaxants 26 Feb, 2025
Active
US7544372 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023 Expired
US7790199 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023 Expired
US7820203 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023 Expired
US7829121 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023 Expired
US8877245 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023 Expired
US9375410 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023 Expired
US9399025 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023 Expired
US7842687 Cephalotaxane derivatives and their processes of preparation and purification 16 Mar, 2019 Expired
USRE45128 Cephalotaxane derivatives and their processes of preparation and purification 16 Mar, 2019 Expired


Given below is the list of recent legal activities going on the following drug patents of Teva Pharms Intl.

Activity Date Patent Number
Patent litigations
Expire Patent 12 Dec, 2022 US7829121 (Litigated)
Expire Patent 12 Dec, 2022 US8877245 (Litigated)
Expire Patent 28 Nov, 2022 US7820203 (Litigated)
Expire Patent 10 Oct, 2022 US7790199 (Litigated)
Maintenance Fee Reminder Mailed 27 Jun, 2022 US7829121 (Litigated)
Maintenance Fee Reminder Mailed 27 Jun, 2022 US8877245 (Litigated)
Maintenance Fee Reminder Mailed 13 Jun, 2022 US7820203 (Litigated)
Maintenance Fee Reminder Mailed 25 Apr, 2022 US7790199 (Litigated)
Expire Patent 12 Jul, 2021 US7544372 (Litigated)
Maintenance Fee Reminder Mailed 25 Jan, 2021 US7544372 (Litigated)
Expire Patent 31 Aug, 2020 US9399025 (Litigated)
Expire Patent 03 Aug, 2020 US9375410 (Litigated)
Expire Patent 20 Jul, 2020 US7387793
Maintenance Fee Reminder Mailed 16 Mar, 2020 US9399025 (Litigated)
Maintenance Fee Reminder Mailed 17 Feb, 2020 US9375410 (Litigated)


Teva Pharms Intl's Family Patents

Teva Pharms Intl drugs have patent protection in a total of 13 countries. It's US patent count contributes only to 39.4% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Teva Pharms Intl Drug List

Given below is the complete list of Teva Pharms Intl's drugs and the patents protecting them.


1. Amrix

Amrix is protected by 8 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7387793 Modified release dosage forms of skeletal muscle relaxants 26 Feb, 2025
(4 months from now)
Active
US7544372 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023
(10 months ago)
Expired
US7790199 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023
(10 months ago)
Expired
US7820203 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023
(10 months ago)
Expired
US7829121 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023
(10 months ago)
Expired
US8877245 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023
(10 months ago)
Expired
US9375410 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023
(10 months ago)
Expired
US9399025 Modified release dosage forms of skeletal muscle relaxants 14 Nov, 2023
(10 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Amrix's drug page


2. Synribo

Synribo is protected by 3 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6987103 Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents 26 Oct, 2026
(2 years from now)
Active
US7842687 Cephalotaxane derivatives and their processes of preparation and purification 16 Mar, 2019
(5 years ago)
Expired
USRE45128 Cephalotaxane derivatives and their processes of preparation and purification 16 Mar, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Synribo's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List